Evaluation of Cardioprotective Potential of Drakshasava in Induced Diabetic Condition

The objective of the present study was to evaluate the effect of Drakshasava- T and Drakshasava-M prepared by traditional and modern methods respectively and marketed Drakshasava on fasting blood glucose and serum lipid profile in alloxan induced diabetic rats. Oral administration of Drakshasava-T, Drakshasava-M and marketed Drakshasava (2 ml/kg p.o.) for 21 days caused a significant decrease in fasting blood glucose (FBG) and showed significant rise in blood glutathione level (GSH) in diabetic rats. Glibenclamide was used as a standard antidiabetic drug (10 mg/kg, p.o). These preparations also caused significant reduction in serum cholesterol, LDL and triglycerides and showed significant rise in serum HDL level in diabetic albino rats. Thus all these preparations were able to maintain the tested parameters near to the normal level significantly.